It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The safety and effectiveness of pazopanib are related to plasma trough concentrations in renal cell carcinoma (RCC); however, data on pazopanib plasma trough concentrations with soft tissue sarcoma (STS) are limited. This study investigated the relationship between plasma trough concentrations and pazopanib safety in 45 Japanese patients with RCC or STS. Among the 33 patients included, the median pazopanib trough concentration was 37.5 (range, 12.1–67.6) µg/mL, which was not significantly different between Japanese RCC and STS patients. The plasma trough concentrations showed significant and positive correlations with aspartate aminotransferase and alanine aminotransferase values in blood samples taken for pharmacokinetic measurements after the administration. The incidence of pazopanib treatment discontinuation were significantly higher in RCC patients (p = 0.027). The primary reason for treatment discontinuation was hepatic dysfunction (5/6, 83.3%). Furthermore, this study revealed that pazopanib trough concentration was affected significantly by proton pump inhibitors but not by histamine 2-receptor blockers. In conclusion, the observed pazopanib trough levels and their safety in the Japanese RCC and STS populations in this study were similar to those of the global population. This is the first study to correlate the hepatotoxicity and pharmacokinetic property of pazopanib plasma trough levels by comparing Japanese patients with RCC or STS.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Japanese Foundation for Cancer Research, Department of Pharmacy, Cancer Institute Hospital, Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131); Showa University, Division of Pharmacokinetics and Pharmacodynamics, Department of Pharmacology, Toxicology and Therapeutics, School of Pharmacy, Tokyo, Japan (GRID:grid.410714.7) (ISNI:0000 0000 8864 3422)
2 Japanese Foundation for Cancer Research, Department of Medical Oncology, The Cancer Institute Hospital, Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131)
3 Japanese Foundation for Cancer Research, Department of Urology, The Cancer Institute Hospital, Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131)
4 Showa University, Division of Pharmacokinetics and Pharmacodynamics, Department of Pharmacology, Toxicology and Therapeutics, School of Pharmacy, Tokyo, Japan (GRID:grid.410714.7) (ISNI:0000 0000 8864 3422)
5 Japanese Foundation for Cancer Research, Department of Pharmacy, Cancer Institute Hospital, Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131)
6 Japanese Foundation for Cancer Research, Department of Pharmacy, Cancer Institute Hospital, Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131); Hoshi University Division of Applied Pharmaceutical Education and Research Ebara, Tokyo, Japan (GRID:grid.412239.f) (ISNI:0000 0004 1770 141X)